SPEAKING
image description

Clinically Speaking Issue 20: March 2026

Smarter Pharmacy Benefits with Better Outcomes

Do those other PBMs leverage clinically-driven, evidence-based data to make the right medication therapy decisions that ensure the health and wellbeing of your members?

Does your PBM have a state-of-the-art population health engine that powers clinically-driven pharmacy care decisions?

EmpiRx Health uses clinically-driven evidence and an advanced proprietary population health engine to guide pharmacy care decisions improving patient wellbeing while reducing drug costs.

In Case You Missed It:

How Pharmacists are Transforming Pharmacy Care by Using AI-Powered Medication Optimization (MO)
Thank you to everyone who attended our webinar “How Pharmacists are Transforming Pharmacy Care by Using AI-Powered Medication Optimization (MO).” We hope you enjoyed our discussion on how Medication Optimization (MO) is transforming the PBM model by combining clinical expertise with advanced technology to drive better health outcomes, improve cost efficiency, and improve the overall member experience. A special thank you to our speakers, Glenn Di Biasi, Fund Administrator for the United Food and Commercial Workers (UFCW) National Health and Welfare Fund and Kimberly Howland, Executive Vice President & Chief Product Development Officer at EmpiRx Health. Thank you, as well, to our moderator Jeff Somar, Chief Commercial Officer at EmpiRx Health, for leading such an engaging conversation. If you missed the webinar, you can watch the recording below.

Pharmacy Benefits Made Simple: How to Choose a PBM That Works for Your Employees and Your Bottom-Line White Paper
Our new white paper “Pharmacy Benefits Made Simple: How to Choose a PBM That Works for Your Employees and Your Bottom-Line” explores how traditional PBM models really operate, why transparency and clinical oversight truly matter in a PBM, and what HR and benefits leaders should look for when choosing their pharmacy benefit partner. It also explains how a pharmacist-led, clinically-driven approach can improve employee health outcomes while delivering substantial cost savings.

At EmpiRx Health we believe that PBMs should prioritize members, while delivering measurable savings and ensuring patients receive the right medication, at the right time, and at the right cost. Read our new white paper below.

Resourceful Finance Pro: California PBM Law May Rest Pharmacy Oversight for Finance
​​California’s new PBM law sets a new standard for accountability and transparency in pharmacy benefits. Our CEO, Danny Sanchez, is quoted in the Resourceful Finance Pro article discussing how EmpiRx Health is already aligned with new PBM reform requirements to help employers ensure that pharmacy benefit savings are real, measurable, and patient-centered. Read the full article in the link below.

2026 Gallagher National Pharmacy and Health Plan Services Educational Forum
We had a fantastic opportunity to spend time with our Gallagher colleagues at the 2026 Gallagher National Pharmacy and Health Plan Services Educational Forum held in Palm Beach Gardens, FL. We want to thank our great Gallagher partner, Gregory Redlinger, Area Vice President, Pharmacy Consulting, for collaborating with us during this annual event. Greg and his team are truly leading the way in pharmacy benefits care, and we are proud to partner with them and all of our Gallagher colleagues.

2026 MercerRx Vendor Expo

Our EmpiRx Health team had the pleasure of participating in the 2026 MercerRx Vendor Expo hosted by Mercer in Nashville, TN. EmpiRx Health team members Jeff Somar, Mathew Garcia, and Kevin Newton were on site connecting with Mercer colleagues and sharing details about the recent launch of our newly expanded Medication Optimization (MO) operating model. Thank you to our great Mercer colleagues for hosting this impactful event and encouraging meaningful collaboration and conversation.

Clinical Success Study

Patient: 52-year-old female
Diagnosis: Neurofibromatosis and GIST
Population Health Management Engine Identified: Clinical concern with potential side effect related to requested therapy.

•  The patient was prescribed Gomekli 2mg capsules twice per day for 21 days. ​​​Our Care Team reviewed the patient’s chart notes and found the patient had a history of vision issues. Gomekli use requires a comprehensive ophthalmic examination and the patient only had one cursory review by an optometrist.

•  Our in-house pharmacist reached out to the prescribing physician to discuss the safety concern and suggested assessment by an ophthalmologist.

•  The prescriber agreed with the pharmacist’s recommendation and the patient was sent for assessment where it was deemed therapy with Gomekli would not be clinically safe based on her history of ophthalmic issues. The patient was counseled and instead prescribed Imatinib 400mg tablets. This has resulted in improved clinical outcomes and measurable cost savings.
​​​​
Annual Clinical Savings for the Plan Sponsor: $217,878